Prelude Therapeutics To Participate in Jefferies Healthcare Conference
31 Mai 2023 - 2:30PM
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a
clinical-stage precision oncology company, announced today that the
company will participate in the Jefferies Healthcare Conference,
taking place in New York City, June 7 to 9, 2023.
Details are as follows: On Wednesday, June 7th, at 8:00
a.m. ET, Kris Vaddi, Ph.D., CEO of Prelude will
participate in a fireside chat. The live webcast is
available here and will be available for replay for 90 days.
Dr. Vaddi, joined by Jane Huang, MD, President and Chief
Medical Officer and Laurent Chardonnet, Chief
Financial Officer, will host one-on-one meetings on June
7th.
About Prelude
Prelude is a clinical-stage precision oncology company
developing innovative drug candidates targeting critical cancer
cell pathways. Prelude’s diverse pipeline is comprised of highly
differentiated, potentially best-in-class proprietary small
molecule compounds aimed at addressing clinically validated
pathways for cancers with selectable underserved patients.
Prelude’s pipeline includes four candidates currently in clinical
development: PRT1419, a potent, selective inhibitor of MCL1;
PRT2527, a potent and highly selective CDK9 inhibitor; PRT3645, a
brain penetrant CDK4/6 inhibitor; and PRT3789 a first-in-class
SMARCA2/BRM protein degrader.
For more information, visit our website and follow us on
LinkedIn and Twitter.
Investor Contact:Lindsey TrickettVice
President, Investor
Relations240.543.7970ltrickett@preludetx.com
Media Contact:Helen Shik Shik Communications
617.510.4373 Helen@ShikCommunications.com
Prelude Therapeutics (NASDAQ:PRLD)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Prelude Therapeutics (NASDAQ:PRLD)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024